Participated · Equity · Nov 2025

Founded in 2024 as a spin-off from the Institut Langevin (CNRS), Owlo focuses on non-invasive, 3D, real-time cellular imaging for IVF. Its core product is an innovative microscope module paired with software and AI that enhances the selection of oocytes and embryos, aiming to increase IVF success rates. The technology translates academic research into a clinical tool designed for embryologists. Owlo plans to secure CE certification and begin clinical deployment by 2026. The company recently secured €1.5 million in funding to advance product development and regulatory work. No revenue or user numbers have been disclosed, underscoring its early-stage, pre-commercial status.

Participated · Equity · Oct 2025

Isentroniq designs plug-and-play wiring architecture for superconducting quantum computers, targeting the thermal and spatial bottlenecks that stall machines at roughly 100 qubits. By shrinking heat load and footprint inside dilution refrigerators, its technology aims to accommodate up to 1,000× more qubits in existing cryostats and ultimately bring the cost of a 1-million-qubit system down to about €50 million. The company follows a fabless model, outsourcing fabrication to specialized partners to accelerate time-to-market and minimize capital expenditure while ensuring industrial-grade quality. Co-founded by superconducting-qubits expert Paul Magnard and repeat founder Théodore Amar, Isentroniq is positioning itself as an essential hardware enabler for quantum players such as Google, IBM, and Alice & Bob that are racing toward 100,000-plus qubit roadmaps. The startup will use its recent financing to advance product development, expand its team, and forge partnerships with quantum system builders. No revenue or user figures were disclosed, but the firm’s long-term vision centers on becoming the standard wiring solution for large-scale superconducting quantum computers.

Participated · Series A · Apr 2025

Chipiron is a French deeptech company developing a compact, lower-cost MRI system designed for use in smaller healthcare facilities, mobile units, and remote regions. The company miniaturises MRI technology into an ultra-low-field, mobile unit to broaden access beyond large hospitals and university medical centers. The $17M Series A will fund completion of development and the construction of its first clinical prototypes. Clinical trials are scheduled to begin in 2026. By 2028 Chipiron aims to have clinical prototypes, secure FDA and CE certifications, and deploy at least 100 commercial units, with a primary focus on the U.S. market. The product targets the global MRI market (estimated at ~$10B) and seeks to make MRI more affordable and flexible for broader patient care.